ASCO 2026 Post-Meeting Analysis: Chinese and Asian Pharma Emerge as First-in-Class Leaders — ivonescimab First China-Originated Drug at ASCO Plenary in 61-Year History

Post-ASCO 2026 analyses confirmed a historic shift in the geography of cancer drug innovation, with Chinese, South Korean, and Japanese companies producing multiple Phase 3 positive results and regulatory milestones at the meeting. In a first for the 61-year history of ASCO, a drug of Chinese origin — ivonescimab (Akeso Biotech's AK112) — was selected for the ASCO Plenary Session, where HARMONi-6 data showed significant overall survival benefit (HR 0.66; median OS 27.9 vs. 23.7 months) over anti-PD-1 + chemotherapy in first-line squamous NSCLC. Kelun-Biotech/Merck's sacituzumab tirumotecan (OptiTROP-Lung05, The Lancet) became the first ADC + IO combination to demonstrate Phase 3 PFS superiority over pembrolizumab monotherapy in first-line PD-L1+ NSCLC (HR 0.35; p<0.0001). China's NMPA simultaneously granted sevabertinib (Bayer/China collaboration) Breakthrough Therapy Designation alongside FDA for first-line HER2-mutant NSCLC. Japan's Eisai secured European licensing rights for taletrectinib (IBTROZI) following US, China, and Japan approvals for ROS1+ NSCLC. BioSpectrum Asia noted that these developments 'marked a defining moment for Asian oncology innovation.' The ASCO 2026 scientific program included 7,000+ abstracts from more than 130 countries, reflecting the increasing globalization of oncology clinical research, with Asian and emerging-market sites contributing significantly to enrollment in pivotal trials. The FDA's willingness to grant expanded access, fast-track designations, and priority reviews based on China-first or multinational trial data reflects the growing global acceptance of non-US-led Phase 3 evidence.